Successful Treatment with Lorlatinib after the Development of Alectinib-Induced Liver Damage in ALK-Positive Non-Small-Cell Lung Cancer: A Case Report

Go Makimoto, Keita Kawakado, Masamoto Nakanishi, Tomoki Tamura, Shoichi Kuyama

Research output: Contribution to journalArticlepeer-review

Abstract

Alectinib is a key drug for treating anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer (NSCLC). Alectinib-induced hepatotoxicity is less common than that through other ALK inhibitors, such as crizotinib or ceritinib. Herein, we describe a case of ALK-positive adenocarcinoma successfully treated with lorlatinib after developing alectinib-induced hepatotoxicity. A 57-year-old Japanese man received alectinib as first-line therapy for ALK-positive NSCLC. After 79 days, alectinib was discontinued because of hepatotoxicity and later restarted at 150 mg/day, inducing hepatotoxicity again after 64 days. Switching to lorlatinib treatment (continued for >4 months) caused no severe adverse effects. Hence, lorlatinib may be useful for patients experiencing alectinib-induced hepatotoxicity.

Original languageEnglish
Pages (from-to)197-201
Number of pages5
JournalCase Reports in Oncology
Volume14
Issue number1
DOIs
Publication statusPublished - Jan 2021
Externally publishedYes

Keywords

  • Alectinib
  • Anaplastic lymphoma kinase
  • Hepatotoxicity
  • Lorlatinib
  • Non-small-cell lung cancer

ASJC Scopus subject areas

  • Oncology

Fingerprint

Dive into the research topics of 'Successful Treatment with Lorlatinib after the Development of Alectinib-Induced Liver Damage in ALK-Positive Non-Small-Cell Lung Cancer: A Case Report'. Together they form a unique fingerprint.

Cite this